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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Moclobemide (MCB) undergoes extensive
both presystemic and systemic metabolism
that can be affected by concomitant drugs.
• Valproic acid (VPA) and carbamazepine
(CBZ) have been found to interact with
psychotropic medications of all classes and
many other drugs; VPA acts as a
broad-spectrum inhibitor, and CBZ as a
potent inducer of a variety of
drug-metabolizing enzymes.
• There have been no previous studies
designed to investigate a potential
pharmacokinetic (PK) interaction between
MCB and VPA or CBZ; however, these agents
are likely to be used concomitantly for the
treatment of depressive disorders.
WHAT THIS STUDY ADDS
• VPA does not significantly affect PK or
metabolism of MCB at steady state.
• CBZ significantly decreases MCB exposure.
This effect is time-dependent, being more
pronounced after 3–5 weeks of
co-administration.
AIM
To assess the impact of valproic acid (VPA) and carbamazepine (CBZ) on
moclobemide (MCB) pharmacokinetics (PK) and metabolism at steady state
in depressive patients.
METHODS
Twenty-one inpatients with recurrent endogenous depression received
MCB (150 mg t.i.d.), either as monotherapy or in combination with VPA
(500 mg b.i.d.) or CBZ (200 mg b.i.d.) in a nonrandomized manner.
Steady-state plasma PK parameters of MCB and its two metabolites, Ro
12-8095 and Ro 12-5637, were derived. Clinical assessments of treatment
efficacy were performed weekly using standard depression rating scales.
RESULTS
CBZ, but not VPA, was associated with decreases in the MCB AUC by 35%
[from 7.794 to 5.038 mg h l-1; 95% confidence interval (CI) -4.84863,
-0.66194; P = 0.01] and Cmax by 28% (from 1.911 to 1.383 mg l-1; 95% CI
-0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41%
(from 0.323 to 0.454 l h-1 kg-1; 95% CI 0.00086, 0.26171; P < 0.05) after 4
weeks of co-administration. MCB through concentrations were also
decreased, on average by 41% (from 0.950 to 0.559 mg l-1; 95% CI -0.77479,
-0.03301; P < 0.05). However, the efficacy in this group of patients was not
inferior to the controls, for several possible reasons. Overall tolerability of all
study medications was good.
CONCLUSIONS
VPA does not significantly affect PK or metabolism of MCB, whereas CBZ
time-dependently decreases MCB exposure, probably by inducing
metabolism of MCB and its major plasma metabolite. The actual clinical
relevance of the observed MCB–CBZ PK interaction needs to be further
evaluated in a more comprehensive study.
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Introduction
Moclobemide (MCB) is a selective and reversible inhibitor
of monoamine oxidase type A (MAO-A), with a broad spec-
trum of antidepressant activity [1]. At therapeutic doses,
MCB lacks adverse anticholinergic effects and significant
negative effects on psychomotor performance, cognitive
function or cardiovascular system [2–4]. Therefore, it is
particularly attractive in the treatment of the elderly or
patients with concurrent somatic illness [1, 2, 4].
MCB is metabolized primarily via oxidative pathways
(metabolized fraction >99%). Four primary and many sub-
sequent metabolic reactions have been identified and a
total of 19 metabolites have been isolated from urine [5].
The principal pathways of MCB metabolism involve C- and
N-oxidation of the morpholine ring to yield its two major
metabolites in plasma, Ro 12-8095 and Ro 12-5637, respec-
tively. Ro 12-5637 retains certain MAO-A inhibitory activity,
but is generally present in low concentrations, whereas the
major plasma metabolite, Ro 12-8095, has no pharmaco-
logical activity [5, 6]. MCB has a short elimination half-life
(1–3 h). Time and dose dependence are observed with
multiple oral administrations in that clearance decreases
with administration during the first week and thereafter
remains constant [6–8].
Mood-stabilizing drugs, including valproic acid (VPA)
and carbamazepine (CBZ), have established effects in the
management of bipolar disorder, especially in mania.
However, these drugs have also been shown to be effective
in both bipolar and unipolar depression, including acute
treatment, prevention of relapse or recurrence, and man-
agement of refractory depression (monotherapy or aug-
mentation) [9–16].
VPA and CBZ have been found to interact with psycho-
tropic medications of all classes and many other drugs
[17–19].VPA acts as a broad-spectrum inhibitor of a variety
of hepatic enzymes, including uridine diphosphate-
glucuronyltranserases (UGTs), epoxide hydrolase, and the
CYP2C enzymes (particularly CYP2C9) [20,21].On the other
hand, CBZ is a potent inducer of several drug-metabolizing
enzymes, including cytochrome P450 monooxygenases
(CYPs), namely CYP3A4, CYP2C9, CYP2C19 and CYP1A2, as
well as UGTs [18, 22, 23]. As a consequence of enzyme
inhibition or induction, plasma concentrations of a
co-administered drug may reach toxic or subtherapeutic
levels, and dosage adjustment may be required to avoid
adverse effects or therapeutic failure [19].To the best of our
knowledge, there have been no previous studies designed
to investigate a potential pharmacokinetic (PK) interaction
between MCB and VPA or CBZ, although data on combina-
tion use of MCB with mood stabilizers, including VPA and
CBZ, in patients with bipolar depression exist in the litera-
ture [24]. However, as MCB undergoes extensive both
presystemic and systemic metabolism [6], there is a rea-
sonable theoretical assumption that interactions might
occur at the absorption and/or elimination level.Therefore,
knowledge of the potential for interactions between MCB
and VPA/CBZ is an important prerequisite for ensuring
optimal therapy during their concomitant use for the treat-
ment of depressive disorders.
The purpose of the present study was to assess the
impact of VPA and CBZ on MCB PK and metabolism at
steady state in hospitalized patients with recurrent
depressive disorder. Together with PK assessments, effi-
cacy and safety of MCB monotherapy and combined
therapy (with VPA or CBZ) were examined and compared
in order to assess the clinical consequences of potential
PK interactions.
Materials and methods
Patients and study design
This was a 5-week, single-centre, nonrandomized, open-
label, parallel-group, steady-state, drug interaction study,
which was carried out in three groups of depressive
patients receiving MCB (150 mg t.i.d. at intervals of 6, 6 and
12 h), either as monotherapy (control group) or in combi-
nation with a single mood stabilizer,VPA (500 mg b.i.d.;VPA
group) or CBZ (200 mg b.i.d.; CBZ group). All study medica-
tions were initiated on the same study day (day 0). The
medications were administered at the end of a meal, as
recommended for MCB [4]. The study was performed in
accordance with the Declaration of Helsinki and its amend-
ments and in compliance with the Guidelines of Good
Clinical Practice, employing a protocol approved by the
Institute of Mental Health Ethics Committee. Written,
informed consent was obtained from all patients.
Hospitalized patients, 18–65 years old, who met the
diagnostic criteria for F33.2, according to the ICD-10 Classi-
fication of Mental and Behavioural Disorders,were included
in the study. Exclusion criteria included psychotic features,
bipolar affective disorder, other primary psychiatric disor-
ders, alcohol or drug abuse, serious somatic illness, abnor-
mal liver or kidney function tests, pregnancy, lactation,
concomitant therapy with other known nonselective cyto-
chrome P450 inducers/inhibitors, specific inducers/
inhibitors of CYP2C19, as well as drugs causing analytical
interference (i.e. those interfering with determination of
MCB or its metabolites in plasma). Other somatic
co-medications were permitted according to clinical needs
(e.g.nonsteroidal anti-inflammatory drugs,antibiotics,etc.),
but substances that interfere with cytochrome P450 isoen-
zymes were avoided. Patients already on chronic therapy
for somatic disorders, such as mild hypertension, were
allowed to continue the corresponding medication at the
same dose provided the co-medication was not considered
to affect MCB PK. Concomitant psychotropic therapy, apart
from the mood stabilizers VPA and CBZ, included benzodi-
azepine anxiolytics and hypnotics, as data from clinical
studies revealed no relevant PK or pharmacodynamic (PD)
interactions between benzodiazepines and MCB [25].
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Blood sampling and analytical method
MCB PK was studied under the expected steady-state con-
ditions (steady-state plasma levels of MCB are reached at
approximately 1 week following dose adjustment [4]).
Plasma samples were collected over the study period of 28
days (starting from day 7), allowing concentration profiles
to be determined after the first morning dose on study
days 14 and 28 (blood samples were drawn just before the
first daily dose and 1, 2, 3, 4, 5 and 6 h post dosing). In
addition, concentrations just before the second daily dose
on study days 7, 21 and 35 were followed. Samples were
stored frozen (-20°C) until analysis.
The concentrations of MCB and its two major metabo-
lites in plasma, Ro 12-8095 (lactam metabolite) and Ro
12-5637 (N-oxide metabolite), were measured using a
developed and validated high-performance liquid chro-
matographic method, as described previously [26]. The
limit of quantification for all the analytes was 0.02 mg l-1.
The accuracy (expressed as a percentage relative error)
ranged from -10.0 to 6.5%, -13.4 to 4.5%, and -10.7 to
4.1% for moclobemide,Ro 12-5637 and Ro 12-8095,respec-
tively. Intraday precision [expressed as a coefficient of
variation (CV)] was in the range 1.9–5.6, 1.5–6.1 and 2.7–
7.1% for moclobemide,Ro 12-5637 and Ro 12-8095,respec-
tively, whereas the interday CV was 3.3–13.1, 3.9–8.1 and
4.0–10.0% for moclobemide, Ro 12-5637 and Ro 12-8095,
respectively. The assay was not affected by concomitant
medications, since the selectivity of the method had been
investigated thoroughly through the method validation
studies, as well as before each patient was enrolled for
concomitant drugs that had not been evaluated for inter-
ference previously.
Clinical assessments
The Newcastle diagnostic scale [27] was used for differ-
ential diagnosis of endogenous and neurotic depression;
the assessment was performed before the initiation
of treatment (day 0). Symptom severity and clinical effi-
cacy were assessed weekly (on days 7, 14, 21, 28 and 35)
using the 17-item Hamilton Depression Rating Scale
(HAMD) [28] and two Clinical Global Impression (CGI)
scales [29], the CGI–Severity of Illness (CGI–S) and the
CGI–Global Improvement scales (CGI–I). The CGI–S
assessed the clinician’s impression of the current state of
the patient’s illness on a seven-point scale (1 = ‘normal/
not at all ill’ to 7 = ‘among the most extremely ill
patients’). The CGI–I assessed the patient’s improvement
or deterioration since the beginning of the study using
the scores, 1 (‘very much improved’) to 7 (‘very much
worse’). Ratings were carried out by the same investigator
at each assessment.
Safety was monitored throughout the study by assess-
ing adverse events (AE) reports, laboratory tests (haemato-
logical and biochemical) and vital signs (blood pressure
and heart rate). The overall tolerability of the treatment
was assessed using a four-point scale (very good, good,
moderate, and poor) [24].
Pharmacokinetic and statistical analysis
To achieve the validity of the PK comparisons, the dose of
MCB was the same in all patients because MCB exhibits
nonlinear, dose-dependent PK [6]. PK parameters were cal-
culated for a 6-h morning dosing interval. All PK analyses
were performed using noncompartmental methods with
WinNonlin®, version 4.1 (Pharsight Corp., Mountain View,
CA, USA). The maximum plasma concentration (Cmax) and
the time to its occurrence (tmax), as well as trough levels
[concentrations obtained just prior to the second daily
dose (Cmin(6))] were read directly from the concentration–
time data. The terminal disposition rate constants of MCB
and the two metabolites (lz) were obtained by log-linear
regression analysis of the terminal phase of the plasma
concentration–time curves. The terminal disposition half-
lives (t1/2) were calculated as ln 2/lz. The areas under the
concentration–time curves within the 6-h dosing interval
at steady state (AUC) for MCB and the two metabolites
were estimated using the trapezoidal rule. The linear rule
was used for the ascending part, and the log trapezoidal
rule for the descending part of the curve, up to the last
measured concentration. The oral clearance of MCB (CL/F)
was calculated as the dose/AUC, and the apparent volume
of distribution based on the terminal phase (Vz/F) as CL/lz.
The average concentration (Cav) of MCB during the 6-h
dosing interval was calculated from the expression AUC/6.
For each metabolite, the metabolic ratios (defined as MCB/
metabolite AUC ratios) were estimated.
A previously developed physiological PK–PD model
[30] was used for estimation of the relationship between
MCB plasma concentration and MAO-A activity. The PD
model parameters were used to simulate the MAO-A inhi-
bition time course from measured plasma levels of MCB.
PK and clinical data were analysed using both paramet-
ric and nonparametric statistical tests. As comparable dif-
ferences were found, only results using parametric tests
were presented.
After testing for homogeneity of variances using the
Levene test, plasma PK parameters of MCB and its two
metabolites were compared among the three patient
groups by analysis of variance (ANOVA), followed by a Dun-
nett’s test to compare the VPA or the CBZ group with the
control group. Statistical analysis was performed on PK
profile 1 (day 14) and PK profile 2 (day 28) of MCB, and the
two metabolites to test for variability and evaluate a time
dependency of potential PK drug–drug interactions. For
each patient group, pairwise comparison (paired t-test) of
the two PK profiles was also performed. For tmax, the non-
parametric tests (Kruskal–Wallis or Wilcoxon’s signed rank
test) were used. ANOVA or c2 test was used to analyse effi-
cacy parameters (the c2 test was performed for propor-
tions). All tests were two-tailed. A value of P < 0.05 was
considered to be statistically significant. Unless otherwise
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stated, data are presented as the means  SD, except for
tmax, which is presented as the median and range.
Results
Characteristics of the study population
A total of 21 inpatients (seven in each group) of both
genders were enrolled, and all patients completed the
study. According to the Newcastle scale, all patients had
the diagnosis of endogenous depression (a score6 [27]).
There were no statistically significant differences in the
mean total scores among the three groups of patients
(7.2 0.8, 6.8 0.6 and 7.6 1.2 in the control, VPA and
CBZ groups, respectively). The complete blood count, and
renal (plasma creatinine) and liver function tests were
normal for all patients.
All patients were White. There were no statistically sig-
nificant age, weight or gender differences among the
groups. The use of additional medications was in compli-
ance with the predefined criteria (i.e. inclusion/exclusion
criteria). Benzodiazepines, followed by b-adrenergic
antagonists and other antihypertensives, were the most
frequently used co-medications in all treatment groups
(Table 1). The proportion of patients on concomitant
therapy with any of these drugs did not significantly differ
among the groups. Other co-medications (cefalexin, raniti-
dine and famotidine) were taken by one patient each.
Patients had already been on the stable doses of all
co-medications prior to study enrolment, and the dosages
were unchanged throughout the study, with the exception
of the antibiotic, which was taken for 9 days. Well-known
PK and PD properties of the concomitant drugs and MCB
did not give any reason to suspect that relevant interac-
tions could occur.
Demographic and medication details for the patients
included in the study are summarized in Table 1.
Pharmacokinetics
Patient compliance was dictated by the fact that medica-
tion was provided by medical personnel. Nevertheless,
noncompliance was observed in one patient in the control
group who missed the morning dose on day 14, as
detected by visual inspection of the plasma
concentration–time curve (no absorption phase). These
data were not taken into account for the calculation of
mean PK parameters, except for the t1/2.
The mean plasma concentration–time profiles of MCB
and the two metabolites on days 14 and 28 for each group
are presented in Figure 1.
On day 14, no statistically significant difference was
observed in any of the calculated PK parameters among
the three groups, except for the tmax of MCB and the t1/2 of
the major plasma metabolite, Ro 12-8095, which were sig-
nificantly lower in CBZ-treated patients compared with the
controls (Table 2). Statistical analysis of PK parameters
of MCB and its metabolites obtained on day 28 again
revealed no difference between the control and VPA
groups; however, Cmax, Cav, the AUC of MCB, as well as the
AUC and t1/2 of Ro 12-8095, were significantly decreased
(by 28, 35, 35, 46 and 60%, respectively) in the CBZ-treated
patients in comparison with the controls. CL/F of MCB was
increased by 41% in the CBZ group (P < 0.05) (Table 2).The
differences in the PK parameters of Ro 12-5637 were all
statistically nonsignificant.
To assess the effect of CBZ on MCB disposition more
fully, a statistical comparison of PK parameters between
days 14 and 28 was performed for each patient group.
There were no statistically significant differences in any PK
parameter for the control and VPA groups, demonstrating
the achievement of steady state. For the CBZ group, a sig-
nificantly decreased Cmax (14.3%), Cav (18.4%) and AUC
(18.4%) of MCB as well as an increased CL/F (18.4%) and
Vz/F (21.4%) were found on day 28 (Table 2), suggesting
that effects of CBZ on MCB PK were time dependent.
Compared with the controls, the mean steady-state
trough levels (Cmin(6)) of MCB were 34–52% lower in CBZ-
treated patients; these differences reached statistical sig-
nificance on days 21–35 (P < 0.05; Table 3). The mean
plasma trough levels of the two metabolites were also
reduced, by 47–65 and 51–68% for Ro 12-5637 and Ro
12-8095, respectively, in comparison with the controls; the
Table 1
Demographic and medication details for the patients included in the study
Control group (n = 7) VPA group (n = 7) CBZ group (n = 7)
Gender distribution 6 F/1 M 5 F/2 M 5 F/2 M
Age (years)* 52  4 48  10 53  8
Body weight (kg)* 64  13 72  13 68  9
Concomitant psychotropic
medication (mg day-1†)
Diazepam (15), bromazepam (4.5–9) Bromazepam (3–12), lorazepam (3),
nitrazepam (5)
Diazepam (10–15), alprazolam (0.5–1),
lorazepam (2–3), nitrazepam (5)
Concomitant nonpsychotropic
medication (mg day-1†)
Atenolol (50), cefalexin (2000), enalapril
(5), nifedipine (40)
Metoprolol (50), enalapril (5–10),
ranitidine (300)
Metoprolol (50), propranolol (20),
famotidine (20), enalapril (5),
amlodipine (5)
*Expressed as mean  SD. †Expressed as a dose range.
A. Rakic Ignjatovic et al.























































































































































Mean ( SEM) steady-state plasma concentrations of moclobemide (A,B) and the two metabolites, Ro 12-5637 (C,D) and Ro 12-8095 (E,F), in patients on
monotherapy (Control group) and combined therapy with valproic acid (VPA group) or carbamazepine (CBZ group). Control ( ); VPA ( ); CBZ ( )
MCB monotherapy vs. combined therapy with VPA or CBZ in depressive patients
Br J Clin Pharmacol / 67:2 / 203
differences were statistically significant on days 28 and 35
for Ro 12-5637 and days 7, 21, 28 and 35 for Ro 12-8095.
There were no statistically significant differences in trough
plasma concentrations of MCB and the two metabolites in
VPA-treated patients compared with the controls.
The average MAO-A inhibition estimated from the
mean steady-state MCB plasma concentrations over a 6-h
dosage interval was 80.7, 79.3 and 76.1% on day 14 for the
control, CBZ and VPA groups, respectively, and 80.8, 77.3
and 72.9% on day 28 for the control, CBZ and VPA groups,
respectively.
Efficacy
All three groups of patients had a similar significant
improvement in HAMD and CGI–S scores; over a 4-week
evaluation period (days 7–35), the mean reduction of
HAMD total score was 38.1 [from 24.0 (3.1) to 14.9
(2.6)], 37.5 [from 22.9 (1.6) to 14.3 (2.7)] and 39.3%
[from 24.0 (2.2) to 14.6 (2.63)], whereas the mean
decline in CGI–S was 39.4 [from 4.7 (0.5) to 2.9 (0.7)],
36.7 [from 4.3 (0.5) to 2.7 (0.8)] and 41.2% [from 4.9
(0.4) to 2.9 (0.7)] for the control, VPA and CBZ groups,
respectively. However, there were no statistically signifi-
Table 2
Steady-state plasma PK parameters of moclobemide (MCB; 150 mg t.i.d.) and its two major metabolites, Ro 12-5637 and Ro 12-8095, in patients on
monotherapy (control group) and combined therapy with valproic acid (500 mg b.i.d.; VPA group) or carbamazepine (200 mg b.i.d.; CBZ group)
Parameter
Control group VPA group CBZ group
Day 14 (n = 6) Day 28 (n = 7) Day 14 (n = 7) Day 28 (n = 7) Day 14 (n = 7) Day 28 (n = 7)
Moclobemide
tmax (h) 2 (1–4) 1 (1–2) 2 (1–3) 1 (1–3) 1 (1–2)* 2 (1–3)
Cmax (mg l-1) 1.82  0.39 1.91  0.34 1.78  0.62 1.86  0.42 1.61  0.25 1.38  0.28*†
Cav (mg l-1) 1.23  0.30 1.30  0.34 1.15  0.46 1.09  0.29 1.03  0.29 0.84  0.16**†
AUC (mg h-1 l-1) 7.36  1.83 7.79  2.02 6.91  2.74 6.52  1.72 6.18  1.75 5.04  0.97**†
CL/F (l h-1 kg-1) 0.35  0.07 0.32  0.06 0.34  0.14 0.35  0.13 0.38  0.12 0.45  0.10*†
t1/2 (h) 3.47  0.56‡ 3.77  1.13 3.85  0.91 3.66  1.13 3.13  0.55 3.17  0.50
Vz/F (l kg-1) 1.70  0.29 1.73  0.49 1.77  0.31 1.75  0.42 1.68  0.36 2.04  0.37†
Ro 12-5637
Cmax (mg l-1) 0.27  0.08 0.28  0.13 0.27  0.15 0.27  0.13 0.19  0.10 0.18  0.09
AUC (mg h-1 l-1) 1.13  0.33 1.26  0.38 1.25  0.85 1.19  0.57 0.79  0.48 0.70  0.43
Metabolic ratio§ 6.74  1.73 6.41  1.72 6.46  2.03 6.16  1.99 11.09  7.12 9.29  4.54
t1/2 (h) 4.58  0.82‡ 4.79  1.18 4.68  1.67 4.54  1.30 3.20  0.71 3.31  1.12
Ro 12-8095
Cmax(mg l-1) 0.67  0.17 0.67  0.15 0.60  0.32 0.55  0.26 0.48  0.14 0.47  0.17
AUC (mg h-1 l-1) 3.41  1.06 3.46  0.92 2.96  1.80 2.72  1.48 2.14  0.61 1.88  0.60*
Metabolic ratio§ 2.36  1.04 2.50  1.24 2.68  1.05 2.71  0.97 3.09  1.18 3.12  1.63
t1/2 (h) 7.62  4.43‡ 7.87  3.38 7.07  3.87 6.31  2.67 3.21  0.61* 3.12  1.23**
*P < 0.05; **P < 0.01 vs. the control group of the same day; †P < 0.05 vs. day 14 (intragroup comparison). ‡n = 7; §AUCMCB/AUCmetabolite. Values are expressed as mean  SD with
the exception of tmax, for which the median (range) is reported.
Table 3
Steady-state trough plasma concentrations (Cmin(6)) of moclobemide (MCB;150 mg t.i.d.) and its two metabolites, Ro 125637 and Ro 12-8095, in patients on
monotherapy (control group, n = 7) and combined therapy with valproic acid (500 mg b.i.d.; VPA group, n = 7) or carbamazepine (200 mg b.i.d.; CBZ group,
n = 7)
Concentration (mg l-1)
Compound Group Day 7 Day 14 Day 21 Day 28 Day 35
MCB Control 1.03  0.29 0.92  0.33† 1.00  0.26 0.84  0.27 0.97  0.31
VPA 1.03  0.51 0.78  0.39 0.77  0.36 0.66  0.26 0.79  0.39
CBZ 0.60  0.27 0.61  0.23 0.60  0.24* 0.51  0.15* 0.47  0.16*
Ro 12-5637 Control 0.19  0.07 0.16  0.04† 0.17  0.03 0.16  0.06 0.20  0.07
VPA 0.20  0.14 0.18  0.13 0.17  0.12 0.15  0.07 0.16  0.06
CBZ 0.08  0.04 0.08  0.07 0.09  0.08 0.08  0.06* 0.07  0.05**
Ro 12-8095 Control 0.59  0.14 0.53  0.17† 0.65  0.20 0.52  0.12 0.63  0.19
VPA 0.47  0.28 0.45  0.32 0.48  0.32 0.42  0.27 0.40  0.22
CBZ 0.26  0.11** 0.26  0.09 0.26  0.05** 0.20  0.09** 0.20  0.07***
*P < 0.05; **P < 0.01; ***P < 0.001 vs. control group. †n = 6. Values are expressed as mean  SD.
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cant differences in the mean improvement per week
among the three groups at any time (P > 0.05). The follow-
ing CGI–I mean scores were observed at the final evalua-
tion: 2.1 (0.7), 2.4 (0.5) and 2.3 (0.5) for the control,
VPA and CBZ groups, respectively, with the difference
being statistically nonsignificant (P > 0.05). Although the
difference among the groups at treatment end-point was
nonsignificant, the proportion of patients with CGI–I score
of 1 or 2 (‘very much improved’ or ‘much improved’) dif-
fered at study week 3: three patients (42.8%) in the CBZ
group and no patients in either the control or VPA groups
(P < 0.05). At week 4, the response rates pointed in the
same direction [four patients (57.1%) in the CBZ group vs.
two patients (28.6%) in both the control and VPA groups],
but this difference failed to reach statistical significance.
Safety
A total of three AEs were reported, one in each patient
group: agitation (control group), sexual dysfunction (VPA
group), and drowsiness (CBZ group). All AEs were mild and
expected, and lasted <3 weeks. No serious AEs were
reported. Furthermore, there were no clinically significant
changes in blood pressure, pulse rate or clinical laboratory
variables throughout the study. Overall tolerability of the
study medications in all patient groups was rated as ‘very
good’ or ‘good’.
Discussion
The obtained steady-state PK parameters of MCB in
patients on monotherapy were in the range of correspond-
ing values reported previously for different multiple oral
dose schedules [6]. As reported previously [5, 6], the
C-oxidized metabolite of MCB (Ro 12-8095) was dominant
in human plasma compared with the N-oxidized metabo-
lite (Ro 12-5637).Since morpholine C-oxidation is catalysed
by CYP2C19 [31], its production is affected by CYP2C19
inducers/inhibitors. Relevant interactions involving this
mechanism have already been described in the literature
(e.g. with cimetidine [32] and omeprazole [33]).We hypoth-
esized that this metabolic pathway might also have been
influenced by VPA and/or CBZ. Morpholine N-oxidation is
predominantly catalysed by flavin-containing monooxy-
genase (FMO) [34], which is not easily induced or readily
inhibited [35], therefore potential drug–drug interactions
including this metabolic pathway are less likely to occur.
The present study, however, showed no statistically sig-
nificant effect of VPA on PK and two major metabolic path-
ways of MCB, although, contrary to our initial expectations,
there was a trend for lower plasma concentrations of MCB
in patients on combined therapy with VPA compared with
the group on monotherapy (Figure 1A,B; Table 3). Concen-
trations of the major plasma metabolite, Ro 12-8095, were
also nonsignificantly decreased in the VPA-treated patients
(Figure 1E,F; Table 3), secondary to the decrease in plasma
concentrations of the parent drug. Although VPA is a well-
known inhibitor of certain metabolic enzymes, an increase
in oral clearance of topiramate (by 13%) [36] and clon-
azepam (by 14%) [37] were reported during VPA concomi-
tant therapy.
Except for the tmax, no statistically significant differences
in the PK parameters of MCB were found on day 14
between CBZ-treated patients and the controls. The differ-
ence in tmax was the consequence of a surprisingly high
value (4 h) observed in one patient in the control group,
probably caused by food (it has been reported that food
ingestion results in no difference in Cmax, CL/F, or relative
bioavailability, but has a significant effect on the rate of
MCB absorption, reflected in changes in tmax [6]). This dif-
ference, however, was considered clinically nonsignificant.
In contrast, a significant decrease in Cmax, Cav and AUC of
MCB was observed in CBZ-treated patients in comparison
with the controls on day 28, indicating reduced bioavail-
ability of MCB in patients on the combination therapy. The
t1/2 of MCB was nonsignificantly decreased (by 16%), in
spite of a significant increase in CL/F of MCB. This may
indicate that the influence of CBZ is greater on the absorp-
tion phase of MCB than on its elimination phase. MCB
undergoes a substantial first-pass metabolism, which
becomes saturated following multiple doses (e.g. bioavail-
ability increases from 56% following a single 100-mg dose
to 90% following dosing with 100 mg t.i.d. for 15 days) [6].
It is possible that CBZ might induce first-pass metabolism
of MCB, thus diminishing its oral bioavailability. The results
of the present study (for both between-group compari-
sons as well as statistical comparison of PK parameters
between days 14 and 28, performed for each group sepa-
rately) suggested that 3–4 weeks were necessary until the
effect of CBZ on MCB PK became statistically significant.
Therefore, the potential effect of CBZ on CYP2C19 activity
in vivo might be a function of time, and this could be a
possible explanation for the conflicting data on this matter
contained in the literature [17, 18, 22, 23, 38, 39].
The finding of reduced plasma concentrations of the
metabolites in patients on combination therapy with CBZ
(Figure 1E,F; Table 3) may be at least partly regarded as a
subsequent result from decreased concentrations of the
parent compound. The plasma disposition kinetics of the
metabolites following multiple administration of thera-
peutic doses of MCB have not been thoroughly deter-
mined previously, as a result of low concentrations at the
usual MCB dosage and/or sampling schedule, which did
not allow a complete description [6]. However, it has been
reported that the plasma concentration of Ro 12-8095 in
extensive metabolizers of CYP2C19 declines with longer
t1/2 than the parent compound, indicating elimination-
limited kinetics of the metabolite, whereas the elimination
of the other metabolite, Ro 12-5637, is formation limited
[31]. A similar situation was observed in the present study
in both patients on monotherapy and combination
therapy with VPA (Figure 1). In the CBZ-treated patients,
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however, plasma concentrations of all three compounds
declined in parallel (Figure 1) with similar t1/2 (Table 2).
Finding of a significantly decreased t1/2 of the major plasma
metabolite in this group of patients compared with the
controls suggested that the metabolism of Ro 12-8095 was
also induced by CBZ, although the 6-h sampling time
might have been too short for accurate determination of
the Ro 12-8095 t1/2 in patients on monotherapy and com-
bination therapy with VPA. It has been reported that the
lactam derivative, Ro 12-8095, undergoes further degrada-
tion to mainly acids with <1% of the oral dose of MCB
being recovered in urine as this metabolite [5, 6]. On day
28, the AUC of Ro 12-8095 was significantly decreased in
CBZ-treated patients compared with the controls, whereas
the metabolic ratio (AUCMCB/AUCRo12-8095) was nonsignifi-
cantly increased, suggesting that the AUC of the parent
compound and the AUC of its major metabolite decreased
in nearly the same proportion.Therefore, if CBZ stimulated
the clearance (CL) of formation of Ro 12-8095, the increase
in its elimination CL would be proportional. It has already
been reported that CBZ, as a broad-spectrum inducer, can
decrease plasma concentrations of both drug and its major
metabolite. Such an effect of CBZ has been described, for
example, for risperidone [40] and simvastatin [41].
In general, higher interindividual variability was
observed in the PK parameters of the two metabolites
compared with the MCB ones, particularly in patients on
combination therapy with VPA or CBZ (Table 2). This is
associated with the variable contribution of different
metabolic pathways and pharmacogenetic behaviour of
the two metabolic enzymes, CYP2C19 and FMO [6, 35],
involved in the principal pathways of MCB metabolism.
Therefore, for a more comprehensive delineation of the
effect of CBZ on MCB metabolism and disposition of the
metabolites, a larger study enrolling previously genotyped
subjects would be required. However, irrespective of
the magnitude of interaction, it is highly unlikely that the
metabolites contribute to any significant extent to the
clinical effects of MCB (see Introduction); thus, further
investigation in this field would probably be of limited
clinical relevance.
The addition of the mood stabilizers, VPA or CBZ, did
not seem to impair safety. No clear differences between
the treatment groups could be shown with respect to
improvement on the clinical rating scales for depression,
although the interpretation of results of clinical assess-
ments is limited by small sample size, study design (open-
label, nonrandomized study, without placebo group) and
short study duration (the duration of the study was insuf-
ficient to draw a definite conclusion on the number of
responders). Despite significantly decreased moclobemide
exposure in patients on combination therapy with CBZ,
the measured efficacy of the treatment in this group of
patients was not inferior to the controls. Moreover, some
indicators of a possible earlier onset of antidepressive
action in patients on combination therapy with MCB and
CBZ were noticed (i.e. higher proportion of patients with
CGI–I score of 1 or 2 found in the CBZ group at earlier
evaluations), although the small number of patients
included precludes a more reliable conclusion. These pre-
liminary observations might have been partly attributable
to the beneficial effects of CBZ on depressive symptoms. It
has been reported that CBZ itself has some acute antide-
pressant efficacy [42] and also potentiates the actions
of antidepressants in patients with depression [14, 15].
However, the estimated difference of 8% in average MAO-A
inhibition between the CBZ group and controls was much
lower than the actual difference in average MCB plasma
concentrations, which might have been another explana-
tion for the lack of clinical manifestations of the decreased
MCB exposure. Therefore, the actual clinical relevance of
the observed PK interaction between MCB and CBZ needs
to be further evaluated in a more comprehensive study of
an adequate design, using higher doses of MCB in combi-
nation with CBZ in order to investigate the possibility of
higher therapeutic efficacy, particularly in patients with
more severe symptomatology (600 mg b.i.d. MCB has been
reported to be the maximum tolerated dose regimen in
healthy subjects [43]).
In conclusion, the statistical analysis of PK parameters
indicates the absence of significant effect of VPA on MCB
PK and metabolism at steady state. CBZ co-administration,
on the other hand, significantly decreases bioavailability of
MCB, and reduces steady-state plasma concentrations of
its major, but pharmacologically inactive, plasma metabo-
lite. Decreased absorption of MCB and enhanced elimina-
tion of both MCB and the metabolite are possible
explanations for the mechanism underlying the observed
PK interaction between MCB and CBZ.
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